OncoMatch/Clinical Trials/NCT04302025
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Is NCT04302025 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Alectinib · Entrectinib · Vemurafenib · Cobimetinib · Pralsetinib · Atezolizumab · SBRT · Chemotherapy · Divarasib — This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK fusion
Molecular testing results...showing at least one of the following abnormalities: ALK fusion
Required: ROS1 fusion
Molecular testing results...showing at least one of the following abnormalities: ...ROS1 fusion
Required: NTRK1 fusion
Molecular testing results...showing at least one of the following abnormalities: ...NTRK1/2/3 fusion
Required: NTRK2 fusion
Molecular testing results...showing at least one of the following abnormalities: ...NTRK1/2/3 fusion
Required: NTRK3 fusion
Molecular testing results...showing at least one of the following abnormalities: ...NTRK1/2/3 fusion
Required: BRAF V600 mutation
Molecular testing results...showing at least one of the following abnormalities: BRAF V600 mutation
Required: RET fusion
Molecular testing results...showing at least one of the following abnormalities: RET fusion
Required: PD-L1 (CD274) expression in 1% tumor cells (≥ 1%)
Molecular testing results...showing at least one of the following abnormalities: PD-L1 expression in ≥ 1% tumor cells as determined by Food and Drug Administration (FDA)-approved test
Required: KRAS G12C
Molecular testing results...showing at least one of the following abnormalities: KRAS G12C mutation
Disease stage
Required: Stage IB, IIA, IIB, IIIA, IIIB (T3N2 ONLY) (other)
Excluded: Stage T4 BY VIRTUE OF MEDIASTINAL ORGAN INVASION, IIIB BY VIRTUE OF N3 DISEASE
Newly diagnosed early-stage NSCLC stages IB, IIA, IIB, IIIA, or selected IIIB (T3N2 only)... Staging should be based on the 8th edition of the American Joint Committee on Cancer (AJCC)/Union Internationale Contre le Cancer (UICC) NSCLC staging system
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate end-organ function
Liver function
Adequate end-organ function
Cardiac function
Adequate cardiac function to be eligible for surgical resection with curative intent
Adequate hematologic and end-organ function; Adequate cardiac function to be eligible for surgical resection with curative intent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- City of Hope - Orange County Lennar Foundation Cancer Center · Irvine, California
- USC Norris Cancer Center · Los Angeles, California
- Cedars-Sinai Medical Center · Los Angeles, California
- University of California Los Angeles - Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04302025 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK fusion is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 fusion is a required biomarker for enrollment.
Does this trial require NTRK1?
Yes, NTRK1 fusion is a required biomarker for enrollment.
What disease stage is eligible?
Stage IB or IIA or IIB or IIIA or IIIB (T3N2 ONLY) is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify